Skip to main content
. 2015 Oct 9;100(6):843–847. doi: 10.1136/bjophthalmol-2015-307000

Table 1.

Subject demographics

Parameter Sequence 1 (QAM/QPM) (n=6) Sequence 2 (QPM/QAM) (n=6) All (n=12)
Age, gender, race and ethnicity
Age (in years)
 Mean 71.5 (±9.0) 65.0 (±8.0) 68.3 (±8.8)
 Median 76 68 69.5
 Min, max 59, 79 50, 71 50, 79
Age, n (%)
 50–59 1 (16.7) 1 (16.7) 2 (16.7)
 60–69 1 (16.7) 3 (50.0) 4 (33.3)
 >69 4 (66.7) 2 (33.3) 6 (50.0)
Gender, n (%)
 Male 4 (66.7) 4 (66.7) 8 (66.7)
 Female 2 (33.3) 2 (33.3) 4 (33.3)
Race, n (%)
 White 4 (66.6) 6 (100.0) 10 (83.3)
 Asian 2 (33.3) 0 (0.0) 2 (16.7)
Ethnicity, n (%)
 Not Hispanic 6 (100.0) 6 (100.0) 12 (100.0)
Diagnosis
Ocular conditions n (%)
 Ocular HTN 1 (16.7) 5 (83.3) 6 (50.0)
 OAG 5 (83.3) 1 (16.7) 6 (50.0)
Previous IOP-lowering drugs, n (%)
 TCAI 4 (66.7) 2 (33.3) 6 (50.0)
 PGA 4 (66.7) 2 (33.3) 6 (50.0)
β-Blocker 2 (33.3) 1 (16.7) 3 (25.0)
 Other 3 (50.0) 2 (33.3) 5 (41.7)
 None 0 (0.0) 1 (16.7) 1 (8.3)

HTN, hypertension; IOP, intraocular pressure; OAG, open-angle glaucoma; PGA, prostaglandin analogue; QAM, once daily morning; QPM, once daily evening; TCAI, topical carbonic anhydrase inhibitors.